Bourgeon Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bourgeon Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-33,000	Closed	-$190K	–	101
2017 Q3	$190K	Sell	33,000 -6,000	-15%	-$21.8K	0.11%	79
2017 Q2	$124K	Buy	39,000 +25,500	+189%	+$80.5K	0.08%	75
2017 Q1	$46K	Sell	13,500 -30,219	-69%	-$85.1K	0.03%	87
2016 Q4	$126K	Buy	43,719 +27,719	+173%	+$98.5K	0.08%	87
2016 Q3	$94K	Sell	16,000 -4,000	-20%	-$14K	0.06%	88
2016 Q2	$60K	Buy	+20,000	New	+$82.1K	0.04%	89
2015 Q1	–	Sell	-25,000	Closed	-$412K	–	112
2014 Q4	$412K	Buy	+25,000	New	+$288K	0.25%	76

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bourgeon Capital Management's DRNA Position: Q4 2017 in Review

Bourgeon Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2017, closing a stake of 33,000 shares — an estimated $190K sold.

Bourgeon Capital Management first reported a position in DRNA in Q4 2014 and held it in 7 quarters. The position peaked at $412K in Q4 2014. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2017.

Bourgeon Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Bourgeon Capital Management sold 33,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2017, an estimated $190K.
Bourgeon Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
Bourgeon Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $412K in Q4 2014.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2017.

Based on Bourgeon Capital Management's 13F filing for Q4 2017, filed 5 Feb 2018.